First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours

BACKGROUND: PM00104 binds guanines at DNA minor grooves, impacting DNA replication and transcription. A phase I study was undertaken to investigate safety, dose-limiting toxicities (DLTs), recommended phase II dose (RP2D), pharmacokinetics (PKs) and preliminary antitumour activity of PM00104 as a 1-...

Descripción completa

Detalles Bibliográficos
Autores principales: Yap, T A, Cortes-Funes, H, Shaw, H, Rodriguez, R, Olmos, D, Lal, R, Fong, P C, Tan, D S, Harris, D, Capdevila, J, Coronado, C, Alfaro, V, Soto-Matos, A, Fernández-Teruel, C, Siguero, M, Tabernero, J M, Paz-Ares, L, de Bono, J S, López-Martin, J A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326684/
https://www.ncbi.nlm.nih.gov/pubmed/22491421
http://dx.doi.org/10.1038/bjc.2012.99

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326684/
https://www.ncbi.nlm.nih.gov/pubmed/22491421
http://dx.doi.org/10.1038/bjc.2012.99

Ejemplares similares